RECRUITINGOBSERVATIONAL
HIBA-Institutional Registry of Amyloidosis
Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
About This Trial
1. Creating a population-based registry system Amyloidosis prospective epidemiological survey * risk factors * diagnosis * prognosis * treatment * monitoring * survival 2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires. 3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.
Who May Be Eligible (Plain English)
Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and/or there is amyloidosis in a biopsy specimen and/or requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis
\*\*Who May Qualify: 1 AND (2 or 3)
1. Patients over 18 years:
2. Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
3. Clinically compatible case of Amyloidosis :
- Who Should NOT Join This Trial:
Refusal to participate in the study or the willing to sign a consent form process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and/or there is amyloidosis in a biopsy specimen and/or requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis
\*\*Inclusion Criteria: 1 AND (2 or 3)
1. Patients over 18 years:
2. Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
3. Clinically compatible case of Amyloidosis :
* Exclusion Criteria:
Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Locations (1)
Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires, Argentina